Market Newsdesk

PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023.

As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages of 18-64.

Under the new terms, Elyxyb will be Preferred with the following prior authorization (PA) criteria:

• Migraine Dx, 18 & Older
• Trial and failure of 1 preferred triptan or contraindication to triptans
• Elyxyb will have a QL of 6 bottles.

“We are pleased to announce our first Elyxyb managed health care win with the Medicaid plan in Indiana, which we believe is an important step to expand utilization of Elyxyb throughout the U.S. Importantly, our diversified portfolio of unique, leading programs will increasingly allow us to offer patients complementary and standalone opioid-sparing outpatient pain management solutions,” said Jaisim Shah, Chief Executive Officer of Scilex Holding Company.

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA^TM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and is pending official minutes in writing from the FDA. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.  Scilex launched its first commercial product ZTlido® in October 2018, in-licensed a commercial product Gloperba® in June 2022, and launched its third FDA-approved product Elyxyb^TM in April 2023. It is also developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, and one Phase 2 and one Phase 1 candidate.  Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with post-herpetic neuralgia, which is a form of post-shingles nerve pain.  Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex in-licensed the exclusive rights to commercialize Elyxyb^TM (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex launched Elyxyb^TM in April 2023, and is planning to commercialize Gloperba® by 2024, and is well-positioned to market and distribute those products.   Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2 study, triple-strength formulation of ZTlido®, for the treatment of acute low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and is expected to initiate Phase 2 trials in 2024.

Scilex Holding Company is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential growth of Elyxyb in managed care plans, the potential benefits related to the addition of Elyxyb to the State of Indiana Medicaid PDL, Scilex’s belief that it is well positioned to continue its growth over the next several years, Scilex’s long-term objectives and commercialization plans, Scilex’s potential to attract new capital, future opportunities for Scilex, Scilex’s future business strategies, the expected cash resources of Scilex and the expected uses thereof; Scilex’s current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding ZTlido®, Gloperba®, ELYXYB®, SP-102 (SEMDEXA™), SP-103 or SP-104, if approved by the FDA; Scilex’s development and commercialization plans; and Scilex’s products, technologies and prospects.  

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to the ongoing COVID-19 pandemic; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials for SP-103 or SP-104 may not be successful; risks that the prior results of the clinical trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is the subject of an exclusive, transferable license to use the trademark by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2023 Scilex Holding Company All Rights Reserved.

SOMERSET, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) —
CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology services for medical practices and health systems nationwide, today announced it recently solidified contracts to serve as the MEDITECH implementation partner for three esteemed healthcare institutions: La Paz Regional Hospital in Arizona, Russell Medical Center in Alabama, and Memorial Hospital and Manor in Georgia.

• La Paz Regional Hospital has chosen medSR as its trusted partner to facilitate the seamless implementation of MEDITECH as a Service (MaaS). This strategic collaboration is aimed at enhancing La Paz Regional Hospital’s healthcare services through the utilization of cutting-edge MEDITECH technology.
• Russell Medical Center initially engaged medSR in late 2022 to oversee the implementation of the MaaS system. Building on their successful partnership, Russell recently expanded its scope to include MEDITECH Expanse lab support, further solidifying their commitment to delivering exceptional patient care.
• Memorial Hospital and Manor have also opted for the implementation of MaaS with the support of medSR. This decision reflects Memorial Hospital and Manor’s dedication to staying at the forefront of medical innovation and providing superior healthcare services to their community.

Dwight Garvin, executive vice president and chief operating officer at medSR, expressed his enthusiasm regarding these significant partnerships, stating, “We are thrilled to finalize these contracts with La Paz Regional Hospital, Russell Medical Center, and Memorial Hospital and Manor. These agreements mark a pivotal moment in medSR’s journey, as we continue to witness a growing number of MEDITECH expansion opportunities. By broadening our MEDITECH relationships, we are not only strengthening medSR’s professional revenue but also securing a promising path for our business growth as we enter 2024.”

With a remarkable three-decade legacy, medSR stands as a highly esteemed MEDITECH implementation partner, celebrated for its successful history of assisting healthcare organizations in seamlessly integrating MEDITECH Expanse. Their knowledge extends across all MEDITECH platforms, including Expanse, Ambulatory, 6.1, 6.0, Client/Server, and MAGIC. Their comprehensive services encompass project management, subject matter experts (SMEs), information technology (IT) staffing, interim leadership, training, and activation. The medSR team, comprised of seasoned professionals, brings extensive MEDITECH and operational experience to ensure that client objectives are not only met but exceeded in a cost-effective manner.

For more information on how medSR can contribute to the transformation of your healthcare organization, please visit medSR.com.

About
CareCloud

CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.

Follow CareCloud on LinkedIn, Twitter and Facebook.

SOURCE CareCloud

Company Contact:

Bill Korn
Chief Strategy Officer
CareCloud
[email protected]

Investor Contact:

Asher Dewhurst
ICR Westwicke
[email protected]

Media Inquiries:

Alexis Feinberg
ICR Westwicke
[email protected]

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) — Calling all Swifties! Angelika Film Centers, affiliates of Reading International, Inc. (NASDAQ: RDI), are ushering fans into a VIP concert movie experience with Taylor Swift: The Eras Tour, opening on Friday, Oct. 13. Following pop icon Taylor Swift as she performs her biggest hits in the record-breaking concert, the film is setting records of its own with advance ticket sales making beautiful box office music for the Angelikas.

“We are delighted to be premiering the Taylor Swift: The Eras Tour concert movie at select Angelika locations,” said Scott Rosemann, division manager for Angelika Film Centers. “Pre-sales for this concert event are the highest for any movie or event we have exhibited in 2022 and 2023. We are thrilled to provide our guests with various opportunities to get further immersed into this unforgettable experience, including exclusive food and beverage specials at participating locations.”

Sure to strike a chord with audiences, Angelika Film Centers will offer complimentary limited edition mini one sheets of the movie poster to Taylor Swift: The Eras Tour moviegoers on a first-come, first-served basis, while supplies last. Uniquely designed and highly collectible cups and popcorn tubs commemorating the epic movie event will be available for purchase at the concession counter, also while supplies last.

The Angelika Film Centers are offering film and concert lovers an exclusive viewing experience via private watch parties, providing Swifties the chance to sing and dance alongside friends and family while viewing the film in their own VIP auditorium. Available from Thursday, Oct. 19, through Sunday, Nov. 5, each watch party will accommodate up to 40 guests and currently may be booked at AngelikaFilmCenter.com or the Angelika Film Center App.

The Angelika Film Centers are also announcing an upcoming 72-hour E-Gift Card flash sale. Those purchasing a $100 E-Gift Card any time from Monday, Sept. 25, at 12:01 a.m. (local time) through Wednesday, Sept. 27, at 11:59 p.m. (local time), will also receive a $30 Bonus E-Gift Card. Available on the Angelika Film Center website and mobile app, the e-cards may be redeemed at both the box office and concession stand allowing film lovers to indulge in traditional movie fare or choose something from each theater’s unique food and beverage menu while enjoying the film of their choice.

The e-cards may be used for Taylor Swift: The Eras Tour and other scheduled concert films such as CARLOS: The Santana Journey Global Premiere (Sept. 23, 24 & 27 at select locations), IU Concert: The Golden Hour (Sept. 28 & 30 at select locations) and K-LOVE Live at Red Rocks (Nov. 6 & 7 at select locations), as well as a slate of other highly anticipated arthouse and blockbuster films. Films scheduled to open during the fall and winter of 2023 include French mystery/thriller Anatomy of a Fall, The Holdovers starring Paul Giamatti, Taika Waititi’s Next Goal Wins, A24’s Dream Scenario, Martin Scorsese’s Killers of the Flower Moon, Marvel Studios’ The Marvels, and DC Comics’ Aquaman and the Lost Kingdom.

Guests will also be able to enjoy upcoming holiday-themed signature programming at select locations such as Hitchcocktober, Four Weeks of Christmas, and a Christmas-themed Pajama Party providing fun for the entire family.

Get the all-access scoop on tickets, showtimes, and more via the Angelika Film Center App and website at www.AngelikaFilmCenter.com. For more information on bookings and available showtimes, or to inquire about arranging larger parties, guests should contact the theater directly. Please follow us on Facebook, X (formerly Twitter), Instagram, and YouTube.

About Reading International, Inc.


Reading International, Inc. (NASDAQ: RDI), an internationally diversified cinema and real estate company, is a leading entertainment and real estate company, engaged in the development, ownership and operation of cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. The family of Reading brands includes cinema brands: Reading Cinemas, Angelika Film Centers, Consolidated Theatres, and the State Cinema in Tasmania; live theatres operated by Liberty Theatres in New York City; and signature property developments, including Newmarket Village, Cannon Park, and The Belmont Common in Australia, Courtenay Central in New Zealand, and 44 Union Square in New York City.

Additional information about Reading can be obtains at the Company’s website at www.ReadingRDI.com.

Cautionary Note Regarding Forward-Looking Statements


This press release contains forward-looking statements within the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “may,” “will,” “expect,” “believe,” “intend,” “future,” and “anticipate” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our expectations regarding the size of the box office of the concert movie in the Consolidated circuit.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed throughout Part I, Item 1A – Risk Factors and Part II, Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the most recently ended fiscal year and our other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this Press Release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

To All:

For investor information contact:

Reading International, Inc.
Gilbert Avanes, Executive Vice President & Chief Financial Officer
Andrzej Matyczynski, Executive Vice President – Global Operations
(213) 235-2240

For media information contact:

Jo Ellen Brantferger
(214) 435-1936

CHARLOTTE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisors Angelo Burns, Larisa Holiday, Eli Montoya and Manny Pedroza have joined LPL Financial’s broker-dealer, RIA and custodial platforms. The team reported having served approximately $260 million in advisory, brokerage and retirement plan assets*, and joins LPL from Corebridge Financial, formerly Valic, part of AIG.

With headquarters in Albuquerque, NM, the diverse practice is led by Senior Advisor Angelo Burns, who joined the industry in 2007. He grew the firm over time, understanding that clients could be better served by a team approach, with each advisor bringing different strengths to the group. The four advisors are joined by Client Services Associate Melinda Martinez.

“We specialize in financial education and breaking down complex financial situations to a place where clients can better understand and be more comfortable with their decisions,” Burns said.

For the past few years, the team has primarily operated in the 403(b) retirement space, working closely with hospitals, universities, schools and other non-profit groups. Looking to expand their services, the team rebranded to Wealth Management and Legacy Planning Group with their move to LPL.

“We’ve met so many wonderful clients through the retirement space, but as those client relationships expanded so have their needs,” Burns said. “This is a service industry and our vision is to be able to go deeper with our client relationships and expand our reach. With this move to LPL, we have access to a large suite of investment products and open architecture platforms that provide choice and flexibility, which allows us to serve clients in a greater capacity.”

Burns also noted that the move to independence allows the team to follow a fiduciary standard, without corporate influence or proprietary investment products.

Scott Posner, LPL Executive Vice President, Business Development, stated, “We welcome Angelo, Larisa, Eli, Manny and Melinda to LPL and applaud their mission to enhance the client experience and offer more services. We are committed to delivering robust resources, business solutions and innovative capabilities that can help our advisors differentiate their practice and succeed at every stage of their business’ lifecycle. We look forward to a long-lasting relationship with the entire team at Wealth Management and Legacy Planning Group.”

Related

Advisors, find an LPL business development representative near you.

About LPL Financial


LPL Financial Holdings Inc. (Nasdaq: LPLA) was founded on the principle that LPL should work for advisors and enterprises, and not the other way around. Today, LPL is a leader in the markets we serve, serving nearly 22,000 financial advisors, including advisors at approximately 1,100 enterprises and at approximately 550 registered investment advisor (“RIA”) firms nationwide. We are steadfast in our commitment to the advisor-mediated model and the belief that Americans deserve access to personalized guidance from a financial professional. At LPL, independence means that advisors and enterprise leaders have the freedom they deserve to choose the business model, services and technology resources that allow them to run a thriving business. They have the flexibility to do business their way. And they have the freedom to manage their client relationships, because they know their clients best. Simply put, we take care of our advisors and enterprises, so they can take care of their clients.

Securities and Advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor. Member FINRA/SIPC. LPL Financial and its affiliated companies provide financial services only from the United States. Wealth Management and Legacy Planning Group and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from year-end 2022.

Connect with Us!

https://twitter.com/lpl

https://www.linkedin.com/company/lpl-financial

https://www.facebook.com/LPLFinancialLLC

https://www.youtube.com/user/lplfinancialllc

Media Contact:



[email protected]


(704) 996-1840

Tracking #480673